Investigation of the T cell metabolic reprogramming during immunotherapy in oncologic patients

• Conditions: C43; Malignant melanoma of skin

• Registration Number: DRKS00023625
• Lead Sponsor: niversitätsklinikum Freiburg

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-12-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

age >18 years, histologically confirmed malignant melanoma, small cell lung cancer or bladder cancer, no previous treatment with an immune checkpoint inhibitor, signed written consent form

Exclusion Criteria

previously diagnosed immunodeficiency syndrome

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Extracellular acidification rate and oxygen consumption rate of T cells as determined by extracellular flux assays (Seahorse) at the beginning of treatment, at the second administration and at the first tumor staging

Secondary Outcome Measures

Name	Time	Method
metabolomics and lipidomics of T cells, cytokine production